POP-OUT | CLOSE

An Information Portal to 108124 Biological Macromolecular Structures

 
VARENICLINE
 
QMR is found in 3 entries
QMR
  •   Chemical Component Summary   Hide
    Name VARENICLINE
    Identifiers (6R,10S)-7,8,9,10-tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxaline
    Formula C13 H13 N3
    Molecular Weight 211.26 g/mol
    Type non-polymer
    Isomeric SMILES
    InChI
    InChI key JQSHBVHOMNKWFT-DTORHVGOSA-N
     
  •   Drug Info: DrugBank Hide
    DrugBank ID DB01273   (Stereoisomeric match)
    Name Varenicline
    Groups
    • approved
    • investigational
    Description Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor. In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A full agonism was displayed on alpha7-receptors. On March 9, 2015, the U.S. Food and Drug Administration warned that Varenicline, in the form of Pfizer Inc's quit-smoking drug, Chantix, has been associated with seizures and that some patients who drink while taking the drug may become aggressive or black out. Pfizer is conducting an additional safety study of the drug, results of which are  expected in late 2015. The FDA said it is keeping the black box in place at least until the results of the trial are announced.
    Synonyms CP-526,555
    Salts Varenicline tartrate
    Brand names
    • Champix
    • Chantix
    Affected organism Humans and other mammals
    Indication For use as an aid in smoking cessation.
    Pharmacology Varenicline is a partial nicotinic acetylcholine receptor agonist, designed to partially activate this system while displacing nicotine at its sites of action in the brain.
    Mechanism of action Varenicline is an alpha-4 beta-2 neuronal nicotinic acetylcholine receptor partial agonist. The drug shows high selectiviyty for this receptor subclass, relative to other nicotinic receptors (>500-fold alpha-3 beta-4, >3500-fold alpha-7, >20,000-fold alpha-1 beta gamma delta) or non-nicotinic receptors and transporters (>2000-fold). The drug competitively inhibits the ability of nicotine to bind to and activate the alpha-4 beta-2 receptor. The drug exerts mild agonistic activity at this site, though at a level much lower than nicotine; it is presumed that this activation eases withdrawal symptoms.
    Route of administration
    • oral
    Categories Nicotinic Agonists
    ATC-Code N07BA03
    CAS number 249296-44-4
    Targets
    Name Sequence search Pharmacological action Actions
    Neuronal acetylcholine receptor subunit alpha-4   Search  yes partial agonist
    Neuronal acetylcholine receptor subunit alpha-7   Search  unknown agonist
    Neuronal acetylcholine receptor subunit alpha-3   Search  unknown partial agonist
    Neuronal acetylcholine receptor subunit alpha-6   Search  unknown partial agonist
     
Ligand Image